Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates. By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
We are seeking an experienced corporate development leader to build and maintain a comprehensive view of the solid tumor oncology landscape, translate scientific and competitive intelligence into clear portfolio priorities, and identify external opportunities that can strengthen Crescent’s pipeline. You will partner cross-functionally with Research, Clinical Development, Business Development, and Executive leadership to evaluate assets, inform strategic decision-making, and prepare decision-oriented recommendations for the executive team and Board.